212 related articles for article (PubMed ID: 10456621)
21. Interference of lupus anticoagulants in prothrombin time assays: implications for selection of adequate methods to optimize the management of thrombosis in the antiphospholipid-antibody syndrome.
Della Valle P; Crippa L; Garlando AM; Pattarini E; Safa O; Viganò D'Angelo S; D'Angelo A
Haematologica; 1999 Dec; 84(12):1065-74. PubMed ID: 10586206
[TBL] [Abstract][Full Text] [Related]
22. [Warfarin or enoxaparin: the choice for the patient with venous thrombosis in the first month of treatment].
Vorob'eva NM; Panchenko EP; Kirienko AI; Dobrovol'skiĭ AB; Titaeva EV; Ermolina OV; Balakhonova TV; Andriiashkin VV; Leont'ev SG
Ter Arkh; 2009; 81(9):57-61. PubMed ID: 19827655
[TBL] [Abstract][Full Text] [Related]
23. Intensive initial oral anticoagulation and shorter heparin treatment in deep vein thrombosis.
Schulman S; Lockner D; Bergström K; Blombäck M
Thromb Haemost; 1984 Dec; 52(3):276-80. PubMed ID: 6397871
[TBL] [Abstract][Full Text] [Related]
24. Fixed-dose versus adjusted-dose warfarin in patients with prosthetic heart valves in a peri-urban impoverished population.
Buchanan-Leel B; Levetan BN; Lombard CJ; Commerford PJ
J Heart Valve Dis; 2002 Jul; 11(4):583-92; discussion 593. PubMed ID: 12150309
[TBL] [Abstract][Full Text] [Related]
25. Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation.
Pengo V; Banzato A; Garelli E; Zasso A; Biasiolo A
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):739-41. PubMed ID: 8292723
[TBL] [Abstract][Full Text] [Related]
26. An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis -- results of the European multicenter ADVENT trial.
Bounameaux H; Ehringer H; Hulting J; Rasche H; Rapold HJ; Zultak M
Thromb Haemost; 1997 Sep; 78(3):997-1002. PubMed ID: 9308743
[TBL] [Abstract][Full Text] [Related]
27. Wide variation in thrombin generation in patients with atrial fibrillation and therapeutic International Normalized Ratio is not due to inflammation.
Gatt A; van Veen JJ; Bowyer A; Woolley AM; Cooper P; Kitchen S; Makris M
Br J Haematol; 2008 Sep; 142(6):946-52. PubMed ID: 18573110
[TBL] [Abstract][Full Text] [Related]
28. Hemorheological alterations and hypercoagulable state in deep vein thrombosis.
Mira Y; Vayá A; Martínez M; Villa P; Santaolaria ML; Ferrando F; Aznar J
Clin Hemorheol Microcirc; 1998 Dec; 19(4):265-70. PubMed ID: 9972663
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT.
Eriksson H; Eriksson UG; Frison L; Hansson PO; Held P; Holmström M; Hägg A; Jonsson T; Lapidus L; Leijd B; Stockelberg D; Säfwenberg U; Taghavi A; Thorsén M
Thromb Haemost; 1999 Mar; 81(3):358-63. PubMed ID: 10102460
[TBL] [Abstract][Full Text] [Related]
30. An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis.
Ramacciotti E; Araújo GR; Lastoria S; Maffei FH; Karaoglan de Moura L; Michaelis W; Sandri JL; Dietrich-Neto F;
Thromb Res; 2004; 114(3):149-53. PubMed ID: 15342210
[TBL] [Abstract][Full Text] [Related]
31. Increased left atrial thrombin generation in mitral stenosis is not reflected in arterial prothrombin fragment 1+2 levels.
Peverill RE; Harper RW; Gan TE; Smolich JJ
Clin Sci (Lond); 2000 Apr; 98(4):501-6. PubMed ID: 10731487
[TBL] [Abstract][Full Text] [Related]
32. Optimal initial dose adjustment of warfarin in orthopedic patients.
Lenzini PA; Grice GR; Milligan PE; Gatchel SK; Deych E; Eby CS; Burnett RS; Clohisy JC; Barrack RL; Gage BF
Ann Pharmacother; 2007 Nov; 41(11):1798-804. PubMed ID: 17911206
[TBL] [Abstract][Full Text] [Related]
33. Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study.
Herlitz J; Holm J; Peterson M; Karlson BW; Haglid Evander M; Erhardt L;
Eur Heart J; 2004 Feb; 25(3):232-9. PubMed ID: 14972424
[TBL] [Abstract][Full Text] [Related]
34. Thrombin generation and coagulation factor activities: evaluation and comparison with the international normalized ratio.
Christensen TD; Jensen C; Larsen TB; Christiansen K; Sørensen B
Blood Coagul Fibrinolysis; 2009 Jul; 20(5):358-65. PubMed ID: 19417631
[TBL] [Abstract][Full Text] [Related]
35. Low-intensity oral anticoagulant plus low-dose aspirin during the first six months versus standard-intensity oral anticoagulant therapy after mechanical heart valve replacement: a pilot study of low-intensity warfarin and aspirin in cardiac prostheses (LIWACAP).
Pengo V; Palareti G; Cucchini U; Molinatti M; Del Bono R; Baudo F; Ghirarduzzi A; Pegoraro C; Iliceto S;
Clin Appl Thromb Hemost; 2007 Jul; 13(3):241-8. PubMed ID: 17636186
[TBL] [Abstract][Full Text] [Related]
36. Contributions of procoagulants and anticoagulants to the international normalized ratio and thrombin generation assay in patients treated with warfarin: potential role of protein Z as a powerful determinant of coagulation assays.
Choi Q; Kim JE; Hyun J; Han KS; Kim HK
Thromb Res; 2013 Jul; 132(1):e70-5. PubMed ID: 23769659
[TBL] [Abstract][Full Text] [Related]
37. Changes of prothrombin fragment 1+2 (F 1+2) as a function of increasing intensity of oral anticoagulation--considerations on the suitability of F 1+2 to monitor oral anticoagulant treatment.
Tripodi A; Cattaneo M; Molteni A; Cesana BM; Mannucci PM
Thromb Haemost; 1998 Mar; 79(3):571-3. PubMed ID: 9531043
[TBL] [Abstract][Full Text] [Related]
38. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation.
Yasaka M; Sakata T; Naritomi H; Minematsu K
Thromb Res; 2005; 115(6):455-9. PubMed ID: 15792675
[TBL] [Abstract][Full Text] [Related]
39. Thrombin generation in non-cardioembolic stroke subtypes: the Hemostatic System Activation Study.
Furie KL; Rosenberg R; Thompson JL; Bauer K; Mohr JP; Rosner B; Sciacca R; Barzegar S; Thornell B; Costigan T; Kistler JP
Neurology; 2004 Sep; 63(5):777-84. PubMed ID: 15365123
[TBL] [Abstract][Full Text] [Related]
40. Discrepant sensitivity of thromboplastin reagents to clotting factor levels explored by the prothrombin time in patients on stable oral anticoagulant treatment: impact on the international normalized ratio system.
Testa S; Morstabilini G; Fattorini A; Galli L; Denti N; D'Angelo A
Haematologica; 2002 Dec; 87(12):1265-73. PubMed ID: 12495900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
